Notices and Activity Reports

U.S. FDA approves first fecal microbiota product

 

On November 30, 2022, the U.S. Food and Drug Administration (FDA) approved FerringPharma’s fecal microbiota product, Rebyota, for the treatment of rCDI, the first time the FDA has approved a fecal microbiota product.

Rebyota is approved for the prevention of recurrent Clostridioides difficile infection (CDI) in patients 18 years of age and older. The drug is intended for patients 18 years of age and older with recurrent CDI who have completed treatment with antibiotic therapy and is administered as a single rectal dose. The application for Rebyota has been designated and approved as a Breakthrough Therapy, Expedited Approval, and Orphan Drug Application.

This approval represents a step forward in the treatment of patients with recurrent CDI,” said Peter Marks of the FDA’s Center for Biologics Evaluation and Research (CBER).

In this study, approximately 1,000 subjects received Rebyota, and the estimated success rate in preventing recurrent CDI was significantly higher in the Rebyota group (70.6%) than in the placebo group (57.5%).

THE FIRST FDA APPROVAL OF A FECAL MICROBIOTA PRODUCT IS EXPECTED TO ACCELERATE THE DEVELOPMENT OF FMT AS A DRUG.

 

 

 

 


Reference Articles

FDA News Release
【FDA Approves First Fecal Microbiota Product】2022.11.30
https://www.fda.gov/news-events/press-announcements/fda-approves-first-fecal-microbiota-product

Felling Press Release
[Felling
Receives U.S. FDA Approval for REBYOTA® (Fecal Microbiota, live-jslm)
– Novel First-in-Class Microbiota-Based Live Biopharmaceutical -] 2022.12.09
https://d2gohj824v350l.cloudfront.net/wp-content/uploads/sites/32/2022/12/08211836/20221209_pressrelease.pdf

Articles about other Notices and Activity Reports

December 19, 2023

Notice of Year-end and New Year holidays

Thank you very much for your continued support of our activities. The Institute will be closed for the year-end and New Year holidays as follows.   【Holiday period】 December 29, 2023 (Fri.) – January 3, 2024 (Wed.) 【start of work】Thursday, January 4, 2024   If you wish to contact us during the […]

December 01, 2023

Received the Small and Medium Enterprise Agency Director-General’s Award for the patent for “FMT using nanobubbles.

We have received the Small and Medium Enterprise Agency Director-General’s Award for our patent for “FMT using nanobubbles,” following the award we received last year for our “nanobubble generator.     This invention greatly improves retention and reduces the burden on the patient compared to conventional FMT by using a composition containing intestinal […]

September 27, 2023 Academic ConferenceMember Physician Speaker Event

第7回学術大会【開催報告】

The “7th Academic Conference” was held on Sunday, September 17, 2023. The event was held simultaneously at the venue and online, and was attended by a large number of people, including medical professionals, general companies, research institutions, patients, and the general public. I would like to take this opportunity to express my gratitude to all […]